{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:53:15Z","timestamp":1793987595959,"version":"4.8.0"},"reference-count":59,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To summarise available evidence regarding the performance metrics of validated prognostic models on cardiovascular and kidney outcomes in adults with type 2 diabetes mellitus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Living systematic review and meta-analysis of observational studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>Medline, Embase, Central, and the Cochrane Database of Systematic Reviews from 1 January 2020 to 17 January 2024.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                  <jats:p>Studies validating prognostic models that predicted all cause and cardiovascular mortality, admission to hospital for heart failure, kidney failure, myocardial infarction, or ischaemic stroke in adults with type 2 diabetes mellitus, including people with established cardiovascular disease or chronic kidney disease, or both. Risk models evaluating composite outcomes were not eligible.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data synthesis<\/jats:title>\n                  <jats:p>For each model and outcome, using a random effects model, the reported discrimination measures were pooled, reported as c statistics. Furthermore, when available, calibration plots were reconstructed and interpreted narratively. The Prediction Model Risk of Bias Assessment (PROBAST) tool was used to assess the risk of bias of each analysed study cohort and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to evaluate our certainty in the evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>6529 publications were identified, of which 35 studies reporting on 13 models were included, all of which were developed for general populations with type 2 diabetes but no established cardiovascular disease or chronic kidney disease. Among the identified models, the Risk Equations for Complications of Type 2 Diabetes (RECODe) and the UK Prospective Diabetes Study Outcomes Model 2 (UKPDS-OM2) evaluated all outcomes except for admission to hospital for heart failure. Relative to a threshold c statistic of 0.7, RECODe had an acceptable discrimination for cardiovascular mortality (0.79, high certainty), probably has an acceptable discrimination for myocardial infarction (0.72, moderate certainty) and stroke (0.71, moderate certainty), and may have an acceptable discrimination for kidney failure (0.76, low certainty). High certainty evidence suggests that UKPDS-OM2 has unacceptable discrimination for myocardial infarction (0.64) and stroke (0.65). RECODe showed acceptable calibration for cardiovascular mortality (high certainty), myocardial infarction (high certainty), and kidney failure (moderate certainty) but had unacceptable calibration for stroke (moderate certainty). UKPDS-OM2 showed acceptable calibration for cardiovascular mortality (moderate certainty), stroke (moderate certainty), and kidney failure (low certainty), but may have unacceptable calibration for myocardial infarction (moderate certainty).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>13 unique models were identified that evaluated cardiovascular and kidney outcomes in patients with type 2 diabetes. Two models, RECODe and UKPDS-OM2, evaluated all outcomes except for admission to hospital for heart failure. Of all the appraised prognostic models, RECODe had acceptable discrimination and calibration in validation studies for most outcomes; although, additional studies directly comparing models are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study registration number<\/jats:title>\n                  <jats:p>PROSPERO, CRD42023423075.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Readers\u2019 note<\/jats:title>\n                  <jats:p>This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This version is the original article.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-001369","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T23:50:15Z","timestamp":1755215415000},"page":"e001369","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic models for cardiovascular and kidney outcomes in people with type 2 diabetes: living systematic review and meta-analysis of observational studies"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-3090","authenticated-orcid":false,"given":"Daniel G","family":"Rayner","sequence":"first","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darsh","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1460-6545","authenticated-orcid":false,"given":"Si-Cheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gou","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Z X","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Division of Nephrology and Hypertension and the Kidney Institute, The University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Manja","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Olav Vandvik","sequence":"additional","affiliation":[{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"},{"name":"Department of Medicine, Lovisenberg Diakonale Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"},{"name":"Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"},{"name":"Ted Rogers Center for Heart Research, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025081416500826000_4.1.e001369.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2025081416500826000_4.1.e001369.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"2025081416500826000_4.1.e001369.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2025081416500826000_4.1.e001369.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01202-x","article-title":"Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis","volume":"15","author":"Fenta","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"2025081416500826000_4.1.e001369.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05640-y"},{"key":"2025081416500826000_4.1.e001369.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63443-4","article-title":"Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice","volume":"10","author":"Jitraknatee","year":"2020","journal-title":"Sci Rep"},{"key":"2025081416500826000_4.1.e001369.7","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0578"},{"key":"2025081416500826000_4.1.e001369.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"2025081416500826000_4.1.e001369.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025081416500826000_4.1.e001369.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"BMJ"},{"key":"2025081416500826000_4.1.e001369.11","doi-asserted-by":"crossref","first-page":"111360","DOI":"10.1016\/j.jclinepi.2024.111360","article-title":"A brief step-by-step guide on conducting a systematic review and meta-analysis of prognostic model studies","volume":"170","author":"Rayner","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2025081416500826000_4.1.e001369.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025081416500826000_4.1.e001369.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025081416500826000_4.1.e001369.14","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319243"},{"key":"2025081416500826000_4.1.e001369.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad260"},{"key":"2025081416500826000_4.1.e001369.16","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1377"},{"key":"2025081416500826000_4.1.e001369.17","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0800800102"},{"key":"2025081416500826000_4.1.e001369.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.11.024"},{"key":"2025081416500826000_4.1.e001369.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"2025081416500826000_4.1.e001369.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111344"},{"key":"2025081416500826000_4.1.e001369.21","first-page":"111200","article-title":"Clinical judgment shows similar and sometimes superior discrimination compared to prognostic clinical prediction models. A systematic review","volume":"2024","author":"Colunga-Lozano","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2025081416500826000_4.1.e001369.22","unstructured":"MAGIC evidence ecosystem foundation. n.d. Available: https:\/\/magicevidence.org\/"},{"key":"2025081416500826000_4.1.e001369.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1548"},{"key":"2025081416500826000_4.1.e001369.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2057"},{"key":"2025081416500826000_4.1.e001369.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1159"},{"key":"2025081416500826000_4.1.e001369.26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","article-title":"Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials","volume":"5","author":"Basu","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025081416500826000_4.1.e001369.27","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2002"},{"key":"2025081416500826000_4.1.e001369.28","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1170"},{"key":"2025081416500826000_4.1.e001369.29","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1736"},{"key":"2025081416500826000_4.1.e001369.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1358"},{"key":"2025081416500826000_4.1.e001369.31","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1210\/jc.2019-00215","article-title":"Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model","volume":"104","author":"Copetti","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081416500826000_4.1.e001369.32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00592-021-01746-2","article-title":"All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease","volume":"58","author":"Copetti","year":"2021","journal-title":"Acta Diabetol"},{"key":"2025081416500826000_4.1.e001369.33","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3734","article-title":"Validation in type 2 diabetes of a metabolomic signature of all-cause mortality","volume":"40","author":"Copetti","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"2025081416500826000_4.1.e001369.34","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02684.x"},{"key":"2025081416500826000_4.1.e001369.35","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0190"},{"key":"2025081416500826000_4.1.e001369.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01726-y","article-title":"High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank","volume":"21","author":"Jin","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2025081416500826000_4.1.e001369.37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jval.2021.09.005","article-title":"Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort","volume":"25","author":"Keng","year":"2022","journal-title":"Value Health"},{"key":"2025081416500826000_4.1.e001369.38","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40273-019-00822-4","article-title":"Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort","volume":"37","author":"Laxy","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"2025081416500826000_4.1.e001369.39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.diabres.2018.01.034","article-title":"Establishment and validation of a prediction model for ischemic stroke risks in patients with type 2 diabetes","volume":"138","author":"Li","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2025081416500826000_4.1.e001369.40","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.14806","article-title":"Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score","volume":"24","author":"Lin","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025081416500826000_4.1.e001369.41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/dom.14311","article-title":"Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts","volume":"23","author":"Pagano","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025081416500826000_4.1.e001369.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01221-w","article-title":"Performance of the recommended ESC\/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus","volume":"20","author":"Prausm\u00fcller","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025081416500826000_4.1.e001369.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003692","article-title":"Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study","volume":"18","author":"Quan","year":"2021","journal-title":"PLoS Med"},{"key":"2025081416500826000_4.1.e001369.44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/dom.14867","article-title":"External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial","volume":"25","author":"Razaghizad","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025081416500826000_4.1.e001369.45","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2489"},{"key":"2025081416500826000_4.1.e001369.46","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2337\/db22-0095","article-title":"Circulating Metabolites Associate With and Improve the Prediction of All-Cause Mortality in Type 2 Diabetes","volume":"71","author":"Scarale","year":"2022","journal-title":"Diabetes"},{"key":"2025081416500826000_4.1.e001369.47","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024094","article-title":"Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis","volume":"11","author":"Segar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025081416500826000_4.1.e001369.48","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0958"},{"key":"2025081416500826000_4.1.e001369.49","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jval.2013.06.001","article-title":"Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort","volume":"16","author":"Tao","year":"2013","journal-title":"Value Health"},{"key":"2025081416500826000_4.1.e001369.50","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0745"},{"key":"2025081416500826000_4.1.e001369.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-017-0671-x","article-title":"Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study","volume":"18","author":"Wan","year":"2017","journal-title":"BMC Nephrol"},{"key":"2025081416500826000_4.1.e001369.52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40273-021-01001-0","article-title":"Macrovascular Risk Equations Based on the CANVAS Program","volume":"39","author":"Willis","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2025081416500826000_4.1.e001369.53","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.dsx.2023.102882","article-title":"Serum cystatin C for risk stratification of prediabetes and diabetes populations","volume":"17","author":"Xiong","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"2025081416500826000_4.1.e001369.54","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1273"},{"key":"2025081416500826000_4.1.e001369.55","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1010539519873487","article-title":"Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations","volume":"31","author":"Yew","year":"2019","journal-title":"Asia Pac J Public Health"},{"key":"2025081416500826000_4.1.e001369.56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2023.05.045","article-title":"WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction","volume":"385","author":"Zhang","year":"2023","journal-title":"Int J Cardiol"},{"key":"2025081416500826000_4.1.e001369.57","doi-asserted-by":"crossref","first-page":"108086","DOI":"10.1016\/j.jdiacomp.2021.108086","article-title":"Validating the UK prospective diabetes study outcome model 2 using data of 94,946 Israeli patients with type 2 diabetes","volume":"36","author":"Zhuo","year":"2022","journal-title":"J Diabetes Complications"},{"key":"2025081416500826000_4.1.e001369.58","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010"},{"key":"2025081416500826000_4.1.e001369.59","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-001369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T23:50:19Z","timestamp":1755215419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjmed-2025-001369"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-001369","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}